BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Zacks News
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
by Kanishka Das
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Why Is BioMarin (BMRN) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints
by Zacks Equity Research
Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A
BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
BioMarin Pharmaceutical (BMRN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
4 Biotechs That Could Be Potential Takeover Targets in 2022
by Ekta Bagri
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
by Zacks Equity Research
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.
BioMarin Pharmaceutical (BMRN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up
by Zacks Equity Research
Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 37%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for BioMarin (BMRN) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 63.64% and -5.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
by Zacks Equity Research
BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.
BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.
Stock Market News for Aug 30, 2021
by Zacks Equity Research
Benchmarks closed higher on Friday with the S&P 500 and Nasdaq hitting fresh all-time highs after Federal Reserve Chair Jerome Powell assured that they might taper bond purchases this year, but interest rate hikes are still far away.
Why Is BioMarin (BMRN) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.
Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips
by Zacks Equity Research
Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 76.67% and 11.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
BioMarin (BMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.